The treatment of acute myeloid leukaemia has remained largely unchanged for the last 30
years since the advent of combination chemotherapy with cytarabine arabinoside and …

CD33 is a suitable target to guide delivery of a toxic moiety to most acute myeloid leukemia
cells. Gemtuzumab ozogamicin (Mylotarg®) is a humanized antiCD33 monoclonal antibody …

Gemtuzumab ozogamicin was recently approved in the United States for the treatment of
older patients with CD33-positive acute myeloid leukemia (AML) in first relapse. However …

Introduction Treatment of acute myeloid leukemia (AML) has changed dramatically in the
past ten years with the approval of targeted agents, the first of which was the anti-CD33 …

Gemtuzumab ozogamicin was withdrawn from the market after being evaluated in
combination with chemotherapy in the frontline treatment of patients aged 18 to 60 years …

Ninety-four adults with newly diagnosed or relapsed/refractory acute myeloid leukemia
(AML) were treated with fractionated doses of gemtuzumab ozogamicin (GO) at one-single …

The feasibility of combining gemtuzumab ozogamicin (GO) with intensive chemotherapy as
first-line treatment of acute myeloid leukemia (AML) was assessed in 72 patients, aged 17 to …

The value of the combination of gemtuzumab ozogamicin (GO) and chemotherapy for the
treatment of acute myeloid leukemia (AML) is currently analyzed within clinical trials. GO (6 …

The objective of this work was to determine the safety and efficacy of gemtuzumab
ozogamicin in patients with poor prognosis acute myeloid leukemia (AML). Patients with the …

Introduction Acute myeloid leukaemia (AML) is a type of cancer in which the bone marrow
makes abnormal myeloblasts (a type of white blood cell), red blood cells or platelets …